SEGMENT REPORTING

3 Months Ended

Mar. 31, 2020

The Company is currently composed of two reportable segments: CCA and OVP. The CCA segment includes Point of Care diagnostic laboratory instruments and consumables, and Point of Care digital imaging diagnostic instruments and software services as well as single use diagnostic and other tests, pharmaceuticals and vaccines, primarily for canine and feline use. These products are sold directly by the Company as well as through independent third-party distributors and through other distribution relationships. CCA segment products manufactured at the Des Moines, Iowa production facility included in the OVP segment's assets are transferred at cost and are not recorded as revenue for the OVP segment. The OVP segment includes private label vaccine and pharmaceutical production, primarily for cattle, but also for other animals including small mammals. All OVP products are sold by third parties under third-party labels.

Summarized financial information concerning the Company's reportable segments is shown in the following tables (in thousands):



Three Months Ended March 31, 2020	Core Companion Animal			Other Vaccines and Pharmaceuticals			Total
Total revenue	$	27,306		$	3,348		$	30,654
Operating loss	(4,180		)	(438		)	(4,618		)
Loss before income taxes	(6,379		)	(438		)	(6,817		)
Capital expenditures	128			82			210
Depreciation and amortization	1,042			332			1,374



Three Months Ended March 31, 2019	Core Companion Animal			Other Vaccines and Pharmaceuticals			Total
Total revenue	$	24,716		$	4,795		$	29,511
Operating loss	(51		)	(24		)	(75		)
Loss before income taxes	(35		)	(24		)	(59		)
Capital expenditures	44			190			234
Depreciation and amortization	947			318			1,265

Asset information by reportable segment as of March 31, 2020 is as follows (in thousands):



As of March 31, 2020	Core Companion Animal		Other Vaccines and Pharmaceuticals		Total
Investments in unconsolidated affiliates	$	7,295	$	—	$	7,295
Total assets	331,932		19,049		350,981
Net assets	255,237		15,401		270,638

Asset information by reportable segment as of December 31, 2019 is as follows (in thousands):



As of December 31, 2019	Core Companion Animal		Other Vaccines and Pharmaceuticals		Total
Investments in unconsolidated affiliates	$	7,424	$	—	$	7,424
Total assets	223,980		20,444		244,424
Net assets	137,072		17,292		154,364